HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM

PHASE2RecruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

August 22, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

December 31, 2027

Conditions
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
Interventions
DRUG

Selinexor 40 mg

Patients will receive 40mg of oral SEL, weekly, beginning after they have completed step-up dosing and are 5 (± 2) days out from administration of the first full treatment dose of bispecific antibody therapy for 12 months or until disease progression.

Trial Locations (1)

27705

RECRUITING

Duke University Health System, Durham

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Duke University

OTHER

NCT06822972 - HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM | Biotech Hunter | Biotech Hunter